ProCE Banner Activity

CME

Incorporating New Therapeutic Strategies in the Treatment of Hodgkin Lymphoma

Multimedia
In this on-demand Webcast of a CCO symposium at ASH 2017, Ranjana Advani, MD, leads an expert panel with Robert W. Chen, MD; Andrew Evens, DO, MSc, FACP; and Pier Luigi Zinzani, MD, PhD, as they review and discuss the latest clinical strategies for managing patients with Hodgkin lymphoma.

Physicians : maximum of 2.00 AMA PRA Category 1 {Credits}

Released: January 24, 2018

Expiration: January 23, 2019

No longer available for credit.

Share

Faculty

Ranjana Advani

Ranjana Advani, MD

Professor of Medicine
Department of Oncology
Stanford University Medical Center
Stanford Cancer Center
Stanford, California

Andrew J. Muir

Andrew J. Muir, MD, MHS

Associate Professor of Medicine
Division of Gastroenterology
Director, Gastroenterology/Hepatology Research
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Merck Oncology

Seagen

Takeda Oncology

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with Hodgkin lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess the results of recent trials of response-adapted frontline therapy in Hodgkin lymphoma and how they will influence clinical practice
  • Choose optimal intensified frontline treatments for patients with advanced Hodgkin lymphoma, incorporating available and emerging treatment options
  • Describe the application and limitations of FDG-PET imaging in the early assessment of response to treatment in Hodgkin lymphoma
  • Plan therapeutic strategies to prevent second relapse after transplantation in patients with Hodgkin lymphoma at risk of progression
  • Evaluate the clinical data on available and promising investigational agents for patients with relapsed/refractory Hodgkin lymphoma
  • Determine optimal sequencing of brentuximab vedotin and immune checkpoint inhibitors in the treatment of patients with Hodgkin lymphoma

Program Director Disclosure

Program Director

Ranjana Advani, MD

Professor of Medicine
Department of Oncology
Stanford University Medical Center
Stanford Cancer Center
Stanford, California

Ranjana Advani, MD, has disclosed that she has received consulting fees from Bayer, Bristol-Myers Squibb, Cell Medica, Genentech/Roche, Gilead Sciences, Juno, NanoString, Pharmacyclics, Spectrum, and Sutro and funds for research support from Agensys, Bristol-Myers Squibb, Celgene, Forty Seven Inc, Genentech/Roche, Janssen, Infinity, Kura, Merck, Millennium, Pharmacyclics, Regeneron, and Seattle Genetics.

Faculty Disclosure

Primary Author

Andrew J. Muir, MD, MHS

Associate Professor of Medicine
Division of Gastroenterology
Director, Gastroenterology/Hepatology Research
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina

Andrew M. Evens, DO, MSc, FACP, has disclosed that he has received consulting fees from AbbVie, Affimed, Amgen, Celgene, Kite Pharma, Merck, Millennium, Novartis, Pharmacyclics, Seattle Genetics, and Spectrum; fees for non-CME/CE services from Celgene; and funds for research support from Millennium/Takeda and Seattle Genetics.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 24, 2018, through January 23, 2019:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in and performance at selecting treatment for individual patients with Hodgkin lymphoma.